Your session is about to expire
← Back to Search
Aumolertinib monotherapy for Non-Small Cell Lung Cancer
Study Summary
This trial is testing a new cancer drug against other existing treatments to see if it is more effective and has fewer side effects. It will last for about 5 years, and patients can keep receiving the treatment if it is helping them.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have severe and ongoing nausea, vomiting, or digestive problems that may prevent you from properly taking the study medication.You have or had a lung disease that was caused by drugs or radiation and required treatment with steroids.You have a history of a heart condition called prolonged QT syndrome or Torsades de Pointes.You are allergic to aumolertinib or osimertinib or any of the ingredients they contain.You are eligible for treatment that aims to cure your non-small cell lung cancer.
- Group 1: Aumolertinib monotherapy
- Group 2: Aumolertinib + platinum-based doublet chemotherapy
- Group 3: Osimertinib monotherapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many locations are responsible for administering this clinical trial?
"The trial is based in four locations: Highlands Oncology Group in Springdale, Arkansas; QCCA - Mission Blood & Cancer in Des Moines, Iowa; SCRI - Tennessee Oncology- Nashville in Nashville, Tennessee; and 5 other sites."
Are there any long-term repercussions to Aumolertinib?
"Aumolertinib's safety is estimated to be a 3. This drug has progressed to Phase 3 clinical trials, which means that while there is data supporting its efficacy, repeated rounds of testing have also supported its safety."
Are new recruits being sought for this experiment?
"That is correct. The clinical trial's page on clinicaltrials.gov reveals that the research is ongoing and still looking for 420 individuals from 5 different locations."
Share this study with friends
Copy Link
Messenger